Protagonist Therapeutics (PTGX) EBT (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of EBT data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 119.57% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at -$115.4 million (down 302.21% YoY), and the FY2025 full-year result was -$129.3 million, down 146.29% from the prior year.
• EBT grew to $2.3 million in Q1 2026, from -$43.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $210.7 million in Q1 2024 to a low of -$66.9 million in Q1 2022.
• A 5-year average of -$6.2 million and a median of -$33.7 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT sank 178.95% in 2022 and soared 724.66% in 2024, its largest moves.
• Tracing PTGX's EBT over 5 years: stood at -$34.9 million in 2022, then jumped by 178.23% to $27.3 million in 2023, then soared by 388.88% to $133.6 million in 2024, then sank by 132.71% to -$43.7 million in 2025, then jumped by 105.22% to $2.3 million in 2026.
• Business Quant data shows PTGX's EBT at $2.3 million in Q1 2026, -$43.7 million in Q4 2025, and -$39.3 million in Q3 2025.